DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: Figure 1a shows a typical immunoblot stained with antibodies against dysferlin (upper bands) and β-tubulin (lower, loading control). Figure 1b shows dysferlin/β-tubulin ratios from five independent experiments. As compared with C25 myoblasts, the expression of dysferlin was reduced by 68%, 87%, 88%, and 83% in DYSF2, DYSF3, AB320, and ER myoblasts, respectively. These results agree with the expected dysferlin expression in these myoblasts [31,32,36,37] and validate these cell lines as in vitro models of dysferlinopathy.